Khona Scientific will apply biomanufacturing technology to create bioidentical steroid hormones suited for EVEXIAS’ leading hormone therapy offerings.
BOULDER, CO, UNITED STATES, July 30, 2026 /EINPresswire.com/ — Khona Scientific, a trailblazer in biomanufacturing approaches for intricate natural product compounds, is pleased to confirm the signing of a Letter of Intent (LOI) with EVEXIAS, a foremost provider of hormone replacement and hormone optimization therapies. Via careful strategizing and thorough verification, the two firms aim to build the steroid hormone supply chain of the future, starting now.
Steroid hormones rank among the body’s most potent chemical messengers. These compounds affect the operation of virtually every organ system and biological process, playing essential roles in metabolism, aging, immune function, reproduction, skeletal integrity, cardiovascular health, and cognitive activity. As a result, shortfalls in steroid hormone levels produce extensive health consequences that can be addressed through personalized hormone therapies like those supplied by EVEXIAS.
Just as insufficient steroid hormone levels can harm patient health, gaps in the steroid hormone supply chain can similarly create difficulties for treatment providers such as EVEXIAS. These supply challenges may be overcome through advancements in steroid hormone manufacturing. At present, these substances are sourced nearly entirely from India and China. Khona Scientific’s move into steroid hormones stems from a goal of offering partners like EVEXIAS additional options for procuring APIs to satisfy rising demand from patients and physicians. Creating resilience via multiple sourcing avenues is the central aim of the partnership between Khona Scientific and EVEXIAS.
The initiative focuses on employing Khona Scientific’s BiDS™ platform to generate bioidentical steroid hormones for incorporation into EVEXIAS’ hormone therapy formulations following stringent validation. BiDS™ is a flexible, adaptable system for manufacturing complex active pharmaceutical ingredients (APIs) using plentiful, low-cost, renewable sugars as raw materials. This technology functions like a ‘molecular assembly line’ – it boosts yield, quality, throughput, and efficiency by arranging enzymes from different pathways in the ideal order within a host cell to synthesize the desired product. This configuration maximizes output and overcomes the constraints inherent in older systems. Consequently, this enables scalable, affordable, on-demand API production that does not rely on specialized inputs. By separating steroid hormone API manufacturing from agricultural supply chains, Khona Scientific’s BiDS™ technology can assist EVEXIAS in maintaining the continuity and uniformity of care for patients receiving its customized hormone therapy protocols.
“Our mission has always been to provide patients and physicians with safe, effective, and dependable treatment options” said Dan DeNeui, CEO of EVEXIAS. “We look forward to exploring how Khona Scientific can contribute to this mission by facilitating supply chain diversification for our hormone therapy offerings.”
Paul Orlady, CEO of Khona Scientific, says, “We are eager to showcase the capabilities of Khona Scientific’s technology by delivering a purpose-built production pipeline that will enhance the supply chain for EVEXIAS’ industry-leading hormone therapy segment. This constitutes an important first step for the Companies’ mutual objective of ensuring better health outcomes for patients seeking relief from a number of conditions.”
Several steroid hormones are included under the LOI, such as progesterone, estradiol, estrone, and estriol. Estradiol is a key treatment for menopausal symptoms like hot flashes and night sweats, as well as for preventing bone loss (osteoporosis). Progesterone is often paired with estradiol in hormone therapy plans to address menopausal symptoms and to provide endometrial protection during treatment. Estradiol and progesterone may also be utilized outside of menopause, including for infertility treatment, managing polycystic ovarian syndrome (PCOS), and in assisted reproductive technologies.
About EVEXIAS
EVEXIAS is a frontrunner in hormone optimization, functional medicine, and proactive longevity care, assisting practitioners in moving beyond symptom management toward precise, root-cause treatment. Through the proprietary EvexiPEL® Method, sophisticated diagnostics, and thorough clinical education, EVEXIAS provides a nationwide network of providers with the tools, training, and ongoing strategic support to deliver personalized, data-driven care with confidence and consistency. By uniting clinical innovation, practice growth strategies, and education-first implementation, EVEXIAS helps enhance patient outcomes, boost practice performance, and shape the future of integrative medicine. Discover more at http://www.evexias.com/.
About Khona Scientific
Khona Scientific is a synthetic biology innovator that deploys modular biomanufacturing solutions for producing complex natural product compounds from renewable, basic feedstocks. The Company’s BiDS™ platform unlocks the full potential of Key Starting Material (KSM) and Active Pharmaceutical Ingredient (API) biomanufacturing by reengineering complex biosynthetic pathways to function as high-throughput molecular assembly lines. Khona Scientific is currently applying its technology to manufacture KSMs and generic APIs where quality, dependability, and flexibility are critical. Learn more at http://www.khonascientific.com/.
Paul Orlady
Khona Scientific Inc.
Paul@khonascientific.com
